Growth Metrics

Ironwood Pharmaceuticals (IRWD) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Ironwood Pharmaceuticals (IRWD) over the last 12 years, with Q3 2025 value amounting to $385.0 million.

  • Ironwood Pharmaceuticals' Non-Current Debt fell 375.0% to $385.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $385.0 million, marking a year-over-year decrease of 375.0%. This contributed to the annual value of $385.0 million for FY2024, which is 2833.33% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Non-Current Debt stood at $385.0 million for Q3 2025, which was down 375.0% from $385.0 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Non-Current Debt's 5-year high stood at $425.0 million during Q2 2024, with a 5-year trough of $275.0 million in Q1 2024.
  • Moreover, its 3-year median value for Non-Current Debt was $385.0 million (2024), whereas its average is $366.5 million.
  • The largest annual percentage gain for Ironwood Pharmaceuticals' Non-Current Debt in the last 5 years was 4000.0% (2025), contrasted with its biggest fall of 941.18% (2025).
  • Over the past 3 years, Ironwood Pharmaceuticals' Non-Current Debt (Quarter) stood at $300.0 million in 2023, then increased by 28.33% to $385.0 million in 2024, then changed by 0.0% to $385.0 million in 2025.
  • Its Non-Current Debt was $385.0 million in Q3 2025, compared to $385.0 million in Q2 2025 and $385.0 million in Q1 2025.